CIK 0001590560
- Large accelerated filer
uniQure N.V.
Sign in to watch- Ticker
- QURE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- Phone
- +1 339-970-7000
- Business address
- PAASHEUVELWEG 25A, AMSTERDAM, Netherlands, 1105 BP
- Former names
- uniQure B.V.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $192,950
- in 1 filing, $193K under 10b5-1 plans
Net −$192,950. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-06 | Meek David D. Director | Sale 10b5-1 | −9,080 | $21.25 | $193K | 30,667 |
| 2026-10-30 | Abi-Saab Walid Chief Medical Officer | Grant or award | +18,750 | 166,985 | ||
| 2026-07-02 | Kapusta Matthew C CEO, Managing Director | Option exercise 10b5-1 | +21,082 | $19.39 | $409K | 540,309 |
| 2026-07-02 | Kapusta Matthew C CEO, Managing Director | Sale 10b5-1 | −9,200 | $44.43 | $409K | 531,109 |
| 2026-07-02 | Kapusta Matthew C CEO, Managing Director | Sale 10b5-1 | −4,282 | $45.43 | $195K | 526,827 |
| 2026-07-02 | Kapusta Matthew C CEO, Managing Director | Sale 10b5-1 | −7,600 | $45.89 | $349K | 519,227 |
| 2026-07-02 | Kapusta Matthew C CEO, Managing Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −21,082 | 0 | ||
| 2026-06-30 | Abi-Saab Walid Chief Medical Officer | Option exercise 10b5-1 | +10,000 | $5.59 | $56K | 178,235 |
| 2026-06-30 | Abi-Saab Walid Chief Medical Officer | Sale 10b5-1 | −10,000 | $46.46 | $465K | 168,235 |
| 2026-06-30 | Abi-Saab Walid Chief Medical Officer | Sale 10b5-1 | −20,000 | $46.40 | $928K | 148,235 |
| 2026-06-30 | Abi-Saab Walid Chief Medical Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −10,000 | 50,500 | ||
| 2026-06-30 | Kaye Jack Director | Option exercise 10b5-1 | +4,107 | $37.00 | $152K | 30,103 |
| 2026-06-30 | Kaye Jack Director | Sale 10b5-1 | −4,107 | $46.49 | $191K | 25,996 |
| 2026-06-30 | Kaye Jack Director | Option exercise 10b5-1 | +17,060 | $20.18 | $344K | 43,056 |
| 2026-06-30 | Kaye Jack Director | Sale 10b5-1 | −17,060 | $46.43 | $792K | 25,996 |
| 2026-06-30 | Kaye Jack Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −4,107 | 0 | ||
| 2026-06-30 | Kaye Jack Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −17,060 | 0 | ||
| 2026-06-26 | Abi-Saab Walid Chief Medical Officer | Sale | −1,434 | $46.86 | $67K | 168,235 |
| 2026-06-25 | Kapusta Matthew C CEO, Managing Director | Option exercise 10b5-1 | +28,716 | $31.71 | $911K | 547,943 |
| 2026-06-25 | Kapusta Matthew C CEO, Managing Director | Sale 10b5-1 | −28,716 | $50.02 | $1.4M | 519,227 |
Page 1 of 13 · 251 trades